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Abstract
Background: Biliary atresia (BA) is a progressive inflammatory disorder of the extrahepatic bile ducts leading to the
obliteration of bile flow. The purpose of this study was to determine serum adiponectin in BA patients and to
investigate the relationship of adiponectin with clinical parameters and liver stiffness scores.
Methods: Sixty BA patients post Kasai operation and 20 controls were enrolled. The mean age of BA patients and
controls was 9.6 ± 0.7 and 10.1 ± 0.7 years, respectively. BA patients were classified into two groups according to
their serum total bilirubin (TB) levels (non-jaundice, TB < 2 mg/dl vs. jaundice, TB ≥ 2 mg/dl) and liver stiffness
(insignificant fibrosis, liver stiffness < 7 kPa vs. significant fibrosis, liver stiffness ≥ 7 kPa). Serum adiponectin levels
were analyzed by enzyme-linked immunosorbent assay. Liver stiffness scores were examined by transient
elastography (FibroScan).
Results: BA patients had markedly higher serum adiponectin levels (15.5 ± 1.1 vs. 11.1 ± 1.1 μg/ml, P = 0.03) and
liver stiffness than controls (30.1 ± 3.0 vs. 5.1 ± 0.5 kPa, P < 0.001). Serum adiponectin levels were significantly
elevated in BA patients with jaundice compared with those without jaundice (24.4 ± 1.4 vs. 11.0 ± 0.7 μg/ml, P <
0.001). In addition, BA patients with significant liver fibrosis had remarkably greater serum adiponectin than
insignificant fibrosis counterparts (17.7 ± 1.2 vs. 9.4 ± 1.1 μg/ml, P < 0.001). Subsequent analysis revealed that
serum adiponectin was positively correlated with total bilirubin, hyaluronic acid, and liver stiffness (r = 0.58, r =
0.46, and r = 0.60, P < 0.001, respectively).
Conclusions: Serum adiponectin and liver stiffness values were higher in BA patients compared with normal
participants. The elevated serum adiponectin levels also positively correlated with the degree of hepatic
dysfunction and liver fibrosis. Accordingly, serum adiponectin and transient elastography could serve as the useful
non-invasive biomarkers for monitoring the severity and progression in postoperative BA.
Background
Biliary atresia (BA) is a progressive, inflammatory, fibro-
sclerotic cholangiopathy resulting in complete oblitera-
tion of the extrahepatic bile ducts [1]. The obstruction
of bile flow leads to worsening cholestasis, hepatic fibro-
sis, biliary cirrhosis, end-stage liver disease, and death
within a few years [2]. Currently, Kasai operation or
hepatoportoenterostomy constitutes the initial surgical
treatment of choice for infants with BA. Although Kasai
procedure can successfully establish bile flow to the gas-
trointestinal tract, a number of BA children progress to
hepatic cirrhosis, portal hypertension and ultimately
require liver transplantation [3]. To date, the etiology
and pathogenesis of BA have not been completely
understood; however, several mechanisms have been
proposed including genetic defects, perinatal viral infec-
tions, morphogenic abnormalities, immune mediated
bile duct injuries, and autoimmune disorders involving
the bile ducts [4,5]. * Correspondence: sittisak_honsawek@hotmail.com
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acid toxicity are three major contributors of liver par-
enchymal destruction and hepatic fibrosis in BA patients
[2]. After hepatic stellate cells (HSC) are activated, these
key effecter cells in hepatic fibrogenesis are transformed
into extracellular matrix-producing myofibroblast. This
process results in the production and the accumulation
of collagen and other extracellular matrix in liver
parenchyma, thus initiating and perpetuating the liver
fibrosis [6,7]. Recent studies showed the role of adipo-
kines in hepatic fibrogenesis of various chronic liver
diseases [8]. In this study, we focused on a unique
adipokine, adiponectin.
Adiponectin, a 244 amino acid polypeptide, is the most
abundant adipokine exclusively produced and secreted by
adipocytes into systemic circulation in trimeric, hexameric,
and larger multimeric high-molecular-weight (HMW)
forms [9,10]. Adiponectin is structurally homologue to
tumor necrosis factor-a (TNF-a); however, these two
molecules antagonize each other’se f f e c t si nt h et a r g e t
organs [11]. Adiponectin exerts its anti-inflammatory
effects through the reduction of pro-inflammatory cyto-
kines release including TNF-a and interleukin-6, and
inducing the expression of anti-inflammatory cytokines,
such as interleukin-10 [12,13]. Adiponectin is also
renowned for its anti-diabetic, anti-atherosclerotic, and
anti-obesity effects. It is believed that adiponectin plays a
protective role in liver diseases. In animal studies, adipo-
nectin-knockout mice developed more severe carbon tet-
rachloride-induced liver fibrosis compared with wild type
mice, and adiponectin injection prior to carbon tetrachlor-
ide treatment could prevent it [14]. In non-alcoholic obese
mice, administration of recombinant adiponectin could
attenuate hepatomegaly, hepatic steatosis, and aminotrans-
ferase abnormality [15]. Moreover, elevated adiponectin
levels correlate positively with the severity of liver cirrhosis
and negatively with hepatic protein synthesis [11,16]. In
contrast, low adiponectin levels have been shown in non-
alcoholic fatty liver disease [17]. Adiponectin levels corre-
late negatively with liver fat and hepatic insulin resistance
in diabetic patients [18]. Adiponectin is currently a subject
of research interest since it has the potential to be a useful
marker for liver fibrosis, and a possible target for a new
therapeutic approach.
Recently, it has been reported that a number of cyto-
kines and growth factors have been studied in BA
patients including osteopontin [19], basic fibroblast
growth factor [20], and stem cell factor [21]. To the best
of our knowledge, there have been no published studied
on serum adiponectin levels from various clinical stages
of BA. This is the first study to evaluate the correlation
of serum adiponectin, liver stiffness and clinical out-
comes in postoperative BA. In the present study, we
postulated that serum adiponectin could be associated
with the severity of clinical outcomes and the liver stiff-
ness in BA patients, and to prove this hypothesis, we
analyzed serum adiponectin and liver stiffness in BA
patients compared with healthy controls. Therefore, the
purpose of this study was to determine serum adiponec-
tin levels collected from BA patients and to examine the
possible correlations of serum adiponectin and outcome
parameters of postoperative BA patients.
Methods
All parents of children were informed of the purpose of
the study and of any interventions involved in this
study. Written informed consents were obtained from
participants’ parents prior to the children entering the
study. This study complied with the ethical guidelines of
the 1975 Declaration of Helsinki, and was approved by
the Institutional Review Board of the Faculty of Medi-
cine, Chulalongkorn University.
Study Population
Sixty BA patients (32 girls and 28 boys with mean age of
9.6 ± 0.7 years) and 20 healthy children (10 girls and 10
boys with mean age of 10.1 ± 0.7 years) were recruited
in this study. All BA patients had undergone hepatic
portojejunostomy with Roux-en-Y reconstruction (origi-
nal Kasai procedure), and they were generally in good
health; no signs of suspected infection or bleeding
abnormalities at the time of blood sampling. None of
them had undergone liver transplantation. Healthy con-
trols who attended the Well Baby Clinic at King Chula-
longkorn Memorial hospital for vaccination had normal
physical findings and no underlying disease. BA patients
were classified into two groups according to serum total
bilirubin (TB), serum alanine aminotransferase (ALT),
and liver stiffness score. Based on their jaundice status,
BA children were divided into a non-jaundice group
(TB < 2 mg/dl) and a persistent jaundice group (TB ≥ 2
mg/dl). Subsequently, BA patients were categorized into
a non-significant fibrosis group (liver stiffness < 7 kPa)
and a significant fibrosis group (liver stiffness≥7k P a ) .
The cut-off point of liver stiffness score for significant
fibrosis was based on the study by Castera L, et al. [22]
with sensitivity of 67% and specificity of 89%.
Laboratory methods
After overnight fast, samples of peripheral venous blood
were collected in the morning from every participant,
centrifuged for 15 min at 1000 × g, and stored immedi-
ately at -80°C for further analysis. Quantitative determi-
nation of adiponectin concentration in serum was
performed using commercially available enzyme-linked
immunosorbent assay (ELISA) (R&D Systems, Inc., Min-
neapolis, MN, USA). According to the manufacturer’s
protocol, 50 μl of recombinant human adiponectin
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well, which has been pre-coated with specific antibody
for adiponectin. After incubating for 2 h at room tem-
perature, every well was washed thoroughly with wash
buffer for 4 times. 200 μl of a horseradish peroxidase-
conjugated monoclonal antibody specific for adiponectin
was then added to each well and incubated for a further
2 h at room temperature. After 4 washes, substrate solu-
tion was pipetted into the wells and then microplate was
incubated for 30 min at room temperature with protec-
tion from light. Lastly, the reaction was stopped by the
stop solution and the color intensity was measured with
an automated microplate reader at 450 nm. The adipo-
nectin concentration was determined by a standard opti-
cal density-concentration curve. Twofold serial dilutions
of recombinant human adiponectin with a concentration
of 3.9-250 ng/ml were used as standards. The manufac-
turer reported precision was 2.5-4.7% (intra-assay) and
5.8-6.9% (inter-assay). The sensitivity of this assay was
0.246 ng/ml.
The liver function tests including serum albumin, total
bilirubin (TB), direct bilirubin (DB), aspatate amino-
transferase (AST), alanine aminotransferase (ALT), and
alkaline phosphatase (ALP) were measured using a Hita-
chi 912 automated machine at the central laboratory of
our hospital. The aspartate aminotransferase to platelets
ratio index (APRI) was calculated as follows: (AST/
upper limit of normal) × 100/platelet count (10
9/l) [23].
Liver stiffness measurement
Transient elastography (FibroScan) measured the liver
stiffness between 25 to 65 mm from the skin surface,
which is approximately equivalent to the volume of a
cylinder of 1 cm wide and 4 cm long. The measure-
ments were performed by placing a transducer probe of
FibroScan on the intercostal space at the area of right
lobe of liver with patients lying in a dorsal decubitus
position with maximal abduction of right arm. The tar-
get location for measurement was a liver portion that
was at least 6 cm thick, and was free of major vascular
structures. The measurements were performed until 10
validated results were achieved with a success rate of at
least 80%. The median value of 10 validated scores was
considered the elastic modulus of the liver, and it was
expressed in kilopascals (kPa).
Statistical analysis
Statistical analysis was performed using SPSS software
version 16.0 for Windows. Mann-Whitney U test was
used to compare the difference of serum adiponectin
concentrations between groups. Correlation between
serum adiponectin levels and other serological markers,
and liver stiffness scores were calculated using Pearson’s
correlation coefficient (r). Data were expressed as mean
±S E M .P-values < 0.05 were considered to be statisti-
cally significant.
Results
Comparisons between BA patients and healthy controls
A total of 60 BA patients and 20 healthy controls were
enrolled in this study. The characteristics of participants
in both groups were demonstrated in Table 1. Mean age
and gender ratio in controls and BA patients were not
different whereas serum adiponectin levels in BA
patients were markedly elevated compared with those in
controls (15.5 ± 1.1 vs. 11.1 ± 1.1 μg/ml, P =0 . 0 3 )
(Figure 1). Furthermore, BA patients had significantly
higher hyaluronic acid than controls (50.3 ± 7.1 vs. 23.9
± 1.5 ng/ml, P = 0.03). Additionally, liver stiffness scores
in BA patients were dramatically higher than those in
controls (30.1 ± 3.0 vs. 5.1 ± 0.5 kPa, P < 0.001).
Comparisons between BA patients with and without
persistent jaundice
We further categorized BA patients into jaundice (n =
20) and non-jaundice group (n = 40). As presented in
Table 2, BA patients with jaundice had significantly
higher serum bilirubin, AST, ALT, ALP, APRI and liver
stiffness values compared to those without jaundice.
Moreover, serum adiponectin levels in BA patients with
persistent jaundice were greater than those in BA
patients without jaundice (24.4 ± 1.4 vs. 11.0 ± 0.7 μg/ml,
P < 0.001) (Figure 2). Similarly, BA patients with signifi-
cant fibrosis (n = 44) possessed remarkably higher serum
Table 1 Demographic data, biochemical characteristics,
and liver stiffness scores of controls and biliary atresia
patients
Variables Controls
(n = 20)
BA Patients
(n = 60)
P-value
Age (years) 10.1 ± 0.7 9.6 ± 0.7 0.1
Gender (Female: Male) 10:10 32:28 0.5
BMI (kg/m
2) 18.5 ± 0.5 18.0 ± 0.6 0.5
Albumin (g/dl) - 4.3 ± 0.1 NA
Total bilirubin (mg/dl) - 2.7 ± 0.5 NA
Direct bilirubin (mg/dl) - 2.2 ± 0.5 NA
AST (IU/l) - 128.1 ± 11.2 NA
ALT (IU/l) - 109.5 ± 10.7 NA
ALP (IU/l) - 431.0 ± 28.0 NA
Platelet count (10
3/mm
3) - 162.7 ± 12.8 NA
APRI - 3.0 ± 0.3 NA
Adiponectin (μg/ml) 11.1 ± 1.1 15.5 ± 1.1 0.03
Hyaluronic acid (ng/ml) 23.9 ± 1.5 50.3 ± 7.1 0.03
Liver stiffness (kPa) 5.1 ± 0.5 30.1 ± 3.0 <0.001
The data was expressed as mean ± SEM. BA, biliary atresia; BMI, body mass
index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP,
alkaline phosphatase; APRI, aspartate aminotransferase to platelets ratio index;
NA, not applicable.
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(17.7 ± 1.2 vs. 9.4 ± 1.1 μg/ml, P < 0.001). We also found
that BA patients with persistent jaundice had substan-
tially higher levels of serum hyaluronic acid than those
without jaundice (93.2 ± 16.7 vs. 28.9 ± 3.4 ng/ml,
P < 0.001).
Further analysis demonstrated that serum adiponectin
levels positively correlated with TB (r = 0.58, P < 0.001),
serum hyaluronic acid (r =0 . 4 6 ,P <0 . 0 0 1 ) ,A S T( r =
0.41, P =0 . 0 0 1 ) ,A L P( r = 0.30, P = 0.02), and liver stiff-
ness values (r = 0.60, P < 0.001). Conversely, serum levels
of adiponectin inversely correlated with serum albumin
(r =- 0 . 6 5 ,P < 0.001). Correlations between serum adipo-
nectin and total bilirubin, hyaluronic acid, liver stiffness,
and serum albumin were shown in Figure 3.
Discussion
Biliary atresia is an intractable liver disorder affecting
infants and children. Despite early diagnosis and success-
ful Kasai operation, the great majority of BA patients
inevitably develop liver fibrosis, portal hypertension, and
liver failure. Therefore, the investigation of fibrogenic
progression in BA is undoubtedly important. Liver biopsy
is considered a gold standard in diagnosing liver fibrosis
and determining its severity. However, it is a painful and
invasive procedure with infrequent but possible life-
threatening complications [24]. Furthermore, there have
been questions concerning the accuracy of liver biopsy,
which is adversely affected sampling errors, intra- and
inter-observer variability. These problems may result in
false staging of liver fibrosis [25,22]. In an attempt to
develop noninvasive methods for the assessment of liver
fibrosis, transient elastography or FibroScan has emerged
as the most promising tool in BA patients [26].
Transient elastography or FibroScan (Echosens, Paris,
France) is a novel, rapid, and non-invasive technique for
measuring the degree of liver fibrosis, and it can be per-
formed in the out-patient setting. The transducer probe
creates mild amplitude and low frequency (50 Hz) vibra-
tion, which induces an elastic shear wave in the tissues
underneath. A pulse-echo ultrasound is used to follow
the propagation of the elastic shear wave and to mea-
sure its velocity, which is in direct proportion to tissue
stiffness [25,22]. According to the equation E = rV
2
(E = Elastic modulus, V = Shear velocity, r = mass den-
sity), the stiffer the tissue is, the faster the wave can
Figure 1 Comparison of serum adiponectin levels in biliary
atresia patients and healthy controls. The data was expressed as
mean ± SEM.
Table 2 Comparison between biliary atresia patients
without and with jaundice
Variables BA Patients
without
jaundice
(n = 40)
BA Patients with
Jaundice
(n = 20)
P-value
Age (years) 9.6 ± 0.9 9.5 ± 1.1 0.5
Gender (Female: Male) 20:20 12:8 0.5
BMI (kg/m
2) 18.2 ± 0.6 17.1 ± 0.6 0.1
Albumin (g/dl) 4.5 ± 0.1 3.9 ± 0.1 <0.001
Total bilirubin (mg/dl) 0.7 ± 0.1 6.5 ± 1.2 <0.001
Direct bilirubin (mg/dl) 0.4 ± 0.1 5.9 ± 1.2 <0.001
AST (IU/l) 98.3 ± 11.6 187.7 ± 18.2 <0.001
ALT (IU/l) 94.1 ± 9.7 140.3 ± 24.5 0.04
ALP (IU/l) 369.8 ± 34.8 553.6 ± 33.9 <0.001
Platelet count (10
3/mm
3) 183.5 ± 15.5 121.2 ± 19.9 0.01
APRI 1.9 ± 0.4 5.0 ± 0.5 <0.001
Adiponectin (μg/ml) 11.0 ± 0.7 24.4 ± 1.4 <0.001
Hyaluronic acid (ng/ml) 28.9 ± 3.4 93.2 ± 16.7 <0.001
Liver stiffness (kPa) 18.5 ± 2.4 53.3 ± 4.3 <0.001
The data was expressed as mean ± SEM. BA, biliary atresia; BMI, body mass
index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP,
alkaline phosphatase; APRI, aspartate aminotransferase to platelets ratio index.
Figure 2 Comparison of serum adiponectin levels in controls,
biliary atresia patients without jaundice, and biliary atresia
patients with jaundice. The data was expressed as mean ± SEM.
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av o l u m eo f1 0 0t i m e sb i g g e rt h a nt h a to b t a i n e df r o m
liver biopsy and is, therefore, a better representative for
the whole liver parenchyma [22].
Hepatic stellate cell activation followed by extracellu-
lar matrix production and accumulation is a major
mechanism contributing to the development of liver
fibrosis [6]. A number of cytokines are believed to play
essential roles in this process and they become topics of
research interest in an attempt to evaluate the use of
serum cytokine as a biochemical marker of liver fibrosis.
In the present study, we investigated the relationship of
serum adiponectin with clinical outcomes and liver stiff-
ness scores in postoperative BA patients.
Adiponectin - also known as complement-related pro-
tein 30 (Acrp30), adipose most abundant gene transcript
(apM1) and adipoQ - is mostly synthesized by adipose tis-
sue [27]. Various animal models and clinical researches
showed that adiponectin mediated anti-obesity, anti-
atherosclerotic, and anti-inflammatory effects [28]. Direct
effects on hepatocytes via a specific receptor (AdipoR2
receptor) and anti-inflammatory properties are partly
mediated by its antagonism against TNF-a [29]. This
raises the postulation on the potential hepatoprotective
role of adiponectin against liver fibrosis and cirrhosis.
However, the possible role of adiponectin in the pathogen-
esis of BA remains as yet unclear.
The present study showed that serum adiponectin
levels were significantly elevated in BA patients com-
pared with healthy controls. In addition, serum adipo-
nectin levels were substantially higher in BA patients
with persistent jaundice than those without jaundice.
Subsequent analysis revealed that serum adiponectin
was positively correlated with serum total bilirubin, sug-
gesting that serum adiponectin was associated with
jaundice status in BA patients. Furthermore, jaundice
status in BA patients seems to be an indicator for intra-
hepatic biliary obstruction. Thus, these findings indicate
Figure 3 Correlation analysis in biliary atresia patients. Serum adiponectin is correlated with (A) total bilirubin (r =0 . 5 8 ,P <0 . 0 0 1 ) ,
(B) hyaluronic acid (r = 0.46, P < 0.001), (C) liver stiffness (r = 0.60, P < 0.001) and (D) albumin (r = -0.65, P < 0.001) in patients with biliary atresia.
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genesis of hepatocellular damage in BA.
To our knowledge, this study demonstrates for the first
time increased serum adiponectin levels in BA patients.
We also found that serum adiponectin positively corre-
lated with AST, ALP, hyaluronic acid, and liver stiffness,
but negatively correlated with serum albumin. These
results support that serum adiponectin is associated with
clinical outcomes (jaundice status, hepatic dysfunction,
and liver fibrosis) in BA patients post Kasai operation. Ele-
vated serum adiponectin has been documented in various
liver diseases, including acute hepatitis, chronic hepatitis,
liver cirrhosis, hepatocellular carcinoma, and primary bili-
ary cirrhosis [11,30-32]. In agreement with our findings,
Tacke and colleagues demonstrated that adiponectin was
increased and associated with inflammation and hepatic
damage in chronic liver disease [11]. Elevated adiponectin
concentrations following bile duct ligation in mice and in
human bile from cholestatic patients suggest that biliary
secretion is involved in adiponectin clearance. High adipo-
nectin levels in patients with liver cirrhosis correlated posi-
tively with the severity of cirrhosis and negatively with
hepatic protein synthesis, indicating that adiponectin
might be used as a marker for liver cell injury [11,16].
These findings suggest that elevated circulating adiponec-
tin is related to hepatic damage and hence reflects liver
dysfunction. Accordingly, our results also revealed that
serum adiponectin was positively associated with degree of
liver stiffness determined using FibroScan. Liver stiffness
values are well correlated with advanced stages of hepatic
fibrosis and cirrhosis in children [33]. Wolf and coworkers
showed that mice received adiponectin before concanava-
lin A treatment developed less hepatic damage [12]. Adi-
ponectin expression was upregulated in concanavalin
A-induced liver failure. Therefore, adiponectin could play
a possible role in the regulation of hepatic inflammation.
Future studies on HMW form of adiponectin may help
identify more pieces of the inflammatory jigsaw of BA;
nevertheless, the challenge remains to piece them together
to originate a rational solid hypothesis pertaining to their
exact role.
S e v e r a lp o s s i b l em e c h a n i s m sm a yb er e s p o n s i b l ef o r
the significant elevation of adiponectin in BA patients,
particularly in those with a poor outcome. Increased
serum adiponectin could be attributable to imbalance
between adiponectin production and adiponectin clear-
ance. In advance BA stages, reduced biliary clearance of
adiponectin may plausibly contribute to elevated serum
adiponectin levels. Moreover, extrahepatic organs can
produce and secrete adiponectin in circulation. The
higher adiponectin levels might be regarded as indicat-
ing hepatic injury and cholestasis in BA patients.
Further clinical studies could render more valuable
information on the pathophysiological roles of adiponec-
tin in BA.
It should be noted, however, that there are some
limitations in this study. Firstly, the sample size of par-
ticipants was not large enough to arrive at definite
conclusions. Secondly, we investigated only those sub-
jects who attended King Chulalongkorn Memorial
Hospital, a tertiary care center, for assessment or treat-
ment of BA. As this investigation was designed as a
cross-sectional study, therefore we could not determine
the causal relationship between adiponectin and liver
fibrosis. Other limitation would be the use of FibroS-
can instead of liver biopsy to evaluate the stage of liver
fibrosis, which was not the definitive diagnosis.
Furthermore, the sensitivity for significant fibrosis of
67% is not high enough to use Castera score as a
screening tool of liver fibrosis in BA patients [22]. Pro-
spective studies with a longitudinal design and hepatic
expression of adiponectin would provide useful infor-
mation on the role of adiponectin in hepatic
fibrogenesis.
Conclusion
This is the first study to demonstrate the elevation of
serum adiponectin, hyaluronic acid, and liver stiffness
values in BA patients. Serum adiponectin were corre-
lated well with clinical parameters and the degree of
liver fibrosis determined by FibroScan. Accordingly,
serum adiponectin, hyaluronic acid, and transient elas-
trography could be used as non-invasive biomarkers
reflecting the severity and progression of disease in BA
patients post Kasai operation. Further studies will be
needed to determine the precise role of adiponectin in
the process of liver fibrogenesis.
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